ライフサイエンスコーパス: revascularization

1 ssel myocardial infarction, or target vessel revascularization).

2 e stent thrombosis, stroke, or urgent vessel revascularization.

3 tal clinical outcomes compared with surgical revascularization.

4 omote macrophage recruitment and accelerated revascularization.

5 uided PCI, driven by a higher rate of repeat revascularization.

6 d ischemic limb events after lower extremity revascularization.

7 mortality, any myocardial infarction, or any revascularization.

8 arction, unstable angina, or urgent coronary revascularization.

9 [95% CI, 1.05-1.15]) was also observed with revascularization.

10 t-term adjunct to aspirin after endovascular revascularization.

11 ischemic stroke, or ischemia-driven coronary revascularization.

12 ntify an individual patient's risk of failed revascularization.

13 ndidates for optimal CAD medical therapy and revascularization.

14 02), compared with those undergoing surgical revascularization.

15 and composite major amputation or peripheral revascularization.

16 he importance of early recognition and early revascularization.

17 rade coronary artery disease (CAD) requiring revascularization.

18 acrophages but produced no defects in muscle revascularization.

19 suscitated cardiac arrest, heart failure, or revascularization.

20 ed prior to the widespread adoption of early revascularization.

21 ction, or clinically indicated target lesion revascularization.

22 utcomes of patients following carotid artery revascularization.

23 ator for up to 6 months after the qualifying revascularization.

24 ohort of patients with symptomatic PAD after revascularization.

25 , nonfatal myocardial infarction, and repeat revascularization.

26 g data on the performance versus deferral of revascularization.

27 c valve implants, 332 (20%) were assigned to revascularization.

28 nonfatal myocardial infarction, or coronary revascularization.

29 increase, potentially altering the need for revascularization.

30 h, myocardial infarction, or ischemia-driven revascularization.

31 varoxaban in peripheral artery disease after revascularization.

32 CAD in identifying patients unlikely to need revascularization.

33 ral myocardial infarction, and target lesion revascularization.

34 sts higher with endovascular versus surgical revascularization.

35 angiography (QCA) on the benefit of complete revascularization.

36 CE, MALE, and MALE including lower extremity revascularization.

37 s to identify those who do not need coronary revascularization.

38 nly 8% of site-level variation in receipt of revascularization.

39 of stroke, myocardial infarction, and repeat revascularization.

40 ), and across elective, urgent, and emergent revascularizations.

41 risk for ischemic events, including coronary revascularizations.

42 AD (0.5% versus 6.5%, P<0.0001), and receive revascularization (0.4% versus 5.8%, [adjusted odds rati

43 sociated with a higher risk of target vessel revascularization (18% versus 7.3%; OR, 3.04 [95% CI, 1.

44 ectomy (8%-IVSR vs. 7%-VSF), lower extremity revascularization (19%-IVSR vs. 16%-VSF), and aortic ane

45 re categorized as: 1) procedural (related to revascularization); 2) definite or probable stent thromb

46 nfarction (MI) who did not receive immediate revascularization; (2) patients who have undergone prima

47 ng ALI hospitalization included endovascular revascularization (39.2%, n=115), surgical bypass (24.6%

48 .43), and clinically indicated target lesion revascularization (5.2% versus 6.5%; P=0.30) did not dif

49 s 52%, and women were less likely to undergo revascularization (50.1% versus 53.6%, P<0.01) compared

50 ated myocardial infarction, or target lesion revascularization (a device-oriented composite endpoint

51 creases in antiplatelet therapy and coronary revascularization after implementation in patients with

52 miEC populations and contribute to alveolar revascularization after injury.

53 However, the extent of endogenous revascularization after MI is insufficient, and MI can o

54 nt differences in 30-day death and unplanned revascularization among the 4 groups.

55 e COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).

56 sought to describe outcomes after peripheral revascularization and assess relationships between post-

57 mation and the disconnect between successful revascularization and functional outcomes.

58 patients with ACS treated with DAPT without revascularization and help support shared decision makin

59 We examined the rates of revascularization and in-hospital mortality among Medica

60 remains unmet therapeutic needs for arterial revascularization and ischemic tissue repair.

61 iography was a better predictor for coronary revascularization and MACE and showed better agreement w

62 ss served as a better predictor for coronary revascularization and MACE than stenosis of 50% and grea

63 the predictive value of CT FFR for coronary revascularization and major adverse cardiac events (MACE

64 ascular-based therapies in patients who need revascularization and meet selection criteria.

65 of capacity for high tissue volume, enriched revascularization and minimal inflammatory damage.

66 MI, nonfatal stroke, or urgent target vessel revascularization and superior in preventing BARC 3 (Ble

67 changes, optimal medical therapy, myocardial revascularization and the use of antiplatelet agents to

68 rt death, myocardial infarction, or coronary revascularization) and major vascular events (major coro

69 tiveness (clinically indicated target lesion revascularization) and safety (composite cardiac death a

70 angiographic findings, treatment (including revascularization), and clinical outcomes of patients wi

71 ember 2017 for MI, CHD (i.e., MI or coronary revascularization), and in Medicare for all-cause mortal

72 ent, 454 patients with at least 1 peripheral revascularization, and 236 patients with at least 1 ampu

73 were obtained including acute limb ischemia, revascularization, and all-cause mortality.

74 d as myocardial infarction, late (>180 days) revascularization, and cardiac death.

75 cardiovascular events (MI, stroke, coronary revascularization, and cardiovascular death) in active v

76 eart failure hospitalization, late (>90 day) revascularization, and death.

77 myocardial infarction, unstable angina with revascularization, and heart failure hospitalization.

78 ular events (myocardial infarction, coronary revascularization, and ischemic stroke).

79 Amputations, peripheral revascularization, and limb ischemic adverse events were

80 ity, ACS, ischemia-driven (unplanned) urgent revascularization, and noncardioembolic ischemic stroke

81 ng for differences in angiographic findings, revascularization, and other confounders.

82 mposite end point), ischemia-driven coronary revascularization, and spontaneous myocardial infarction

83 cular death, myocardial infarction, coronary revascularization, and stroke through December 31, 2016.

84 l CABG is underused in contemporary surgical revascularization, and targeted referral of younger pati

85 ion, 180 strokes, 65 atrial fibrillation, 29 revascularizations, and 246 CVD deaths; 792 in the inter

86 d all coronary revascularizations, recurrent revascularizations, and revascularization subtypes.

87 y disease who have undergone lower-extremity revascularization are at high risk for major adverse lim

88 iveness data on endovascular versus surgical revascularization are lacking.

89 o determine whether the benefits of complete revascularization are sustained long-term and their impa

90 10-predictor BN accurately predicted failed revascularization: area under the receiver operating cha

91 tal myocardial infarction, and target vessel revascularization at 30 days (11.7% versus 12.9%, P=0.82

92 ents were more likely to be free from repeat revascularization at 6 years than HCR patients (88.2% ve

93 are less likely to receive statin or undergo revascularization at 90 days compared with men.

94 By multivariable analysis, revascularization at ACS time was associated with a redu

95 lated MI, or clinically driven target lesion revascularization) at 24 months.

96 ath, myocardial infarction, or target vessel revascularization) at 30 days.

97 infarction, stroke, heart failure, coronary revascularization, atrial fibrillation, or CVD death, ir

98 tion, thereby reducing the need for elective revascularization before hospital discharge.

99 o-severe intermittent claudication to either revascularization + best medical therapy + structured ex

100 Patients undergoing peripheral artery revascularization between January 1, 2009, and September

101 ween females and males; however, the optimal revascularization beyond 5 years according to sex has no

102 In conclusion, in AMI managed with revascularization, both BB and ACEI/ARB were associated

103 ease death, myocardial infarction, or urgent revascularization by 23% (hazard ratio, 0.77; 95% CI, 0.

104 of EC apoptosis may promote ischemic tissue revascularization by preserving ECs within ischemic tiss

105 econdary outcomes including stroke, coronary revascularization, cardiovascular mortality, and all-cau

106 cluded any stroke, ischemic stroke, coronary revascularization, cardiovascular mortality, and all-cau

107 Revascularization compared with medical therapy alone wa

108 frequent history of surgical or percutaneous revascularization compared with men.

109 rdial infarction or ischemia-driven coronary revascularization (composite end point), cardiovascular

110 gher neutrophil count on admission and after revascularization correlates positively with major adver

111 adverse cardiovascular events after complete revascularization (CR) than after incomplete revasculari

112 used percutaneous coronary intervention for revascularization, deferred revascularization remained a

113 STEMI and the lack of coronary revascularization determined an increased risk.

114 ve strategy with angiographic assessment and revascularization did not reduce clinical events among p

115 Routine coronary revascularization does not reduce perioperative risk and

116 is, myocardial infarction, and target lesion revascularization during follow-up.

117 ability to manage their disease and hospital revascularization experience, open surgery first was ass

118 rug-eluting stent is the most common mode of revascularization for coronary artery disease.

119 The long-term benefit of revascularization for intermittent claudication is poorl

120 egies for atherosclerosis following coronary revascularization for patients with and without a tradit

121 -term cardiovascular and limb outcomes after revascularization for peripheral artery disease and, in

122 Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonst

123 we identified 32 911 patients who underwent revascularization for symptomatic PAD.

124 iderably over time in patients who underwent revascularization for symptomatic PAD.

125 c evidence in support of medical therapy and revascularization for the management of patients with st

126 rgical technique, including bronchial artery revascularization, for incorporation into the overarchin

127 s with AMI who underwent inhospital coronary revascularization from January 2007 to December 2013 wer

128 is associated with altered expression of pro-revascularization genes in skeletal muscle and macrophag

129 of the 2016 patients (7.8%) in the complete-revascularization group as compared with 213 of the 2025

130 has previously been reported superior in the revascularization group at 1- and 2-year follow-up.

131 l therapy + structured exercise therapy (the revascularization group) or best medical therapy + struc

132 cause death, myocardial infarction, and late revascularization (>90 days), were examined.

133 group), patients who underwent endovascular revascularization had significantly lower in-hospital mo

134 medical therapy, the role of coronary artery revascularization has decreased and is largely confined

135 P=0.01) and increased risk of target vessel revascularization (hazard ratio, 1.82; 95% CI, 1.10-2.94

136 ity at 1 year compared with angiography-only revascularization (hazard ratio: 0.57; 95% confidence in

137 to 1.40) and major amputation or peripheral revascularization (hazard ratio: 8.13; 95% confidence in

138 e-varying myocardial infarction and coronary revascularization (hazard ratios: SB, 1.00, 1.11, 1.27;

139 Hybrid coronary revascularization (HCR) combines both.

140 Hybrid coronary revascularization (HCR) treats multivessel coronary arte

141 ent CHD events (ie, recurrent MI or coronary revascularization), heart failure hospitalization, and a

142 <0.001) but not MALE or MALE/lower extremity revascularization (HR, 1.02 [95% CI, 0.84-1.23], P=0.824

143 nd an increased risk of MALE/lower extremity revascularization (HR, 1.08 [95% CI, 1.04-1.11]; P<0.001

144 In multivariable modeling, smoking, prior revascularization, hypertension, unstable angina, female

145 revascularization (CR) than after incomplete revascularization (ICR) in patients with multivessel dis

146 ction [MI], or ischemia-driven target lesion revascularization [ID-TLR]) as well as its individual co

147 ction [MI], or ischemia-driven target lesion revascularization [ID-TLR]), and target lesion failure (

148 ategy consisting of coronary angiography and revascularization (if appropriate) added to medical ther

149 Whether revascularization improves prognosis in stable ischemic

150 n was performed in 5008 (47.8%) and surgical revascularization in 5476 (52.2%).

151 SET first, followed by endovascular or open revascularization in case of insufficient effect.

152 vel minimally invasive procedure for carotid revascularization in high-risk patients that is associat

153 on, we provide practical recommendations for revascularization in patients with high-risk multivessel

154 Estimating the likely success of limb revascularization in patients with lower-extremity arter

155 ical trials that have assessed the effect of revascularization in patients with stable coronary disea

156 coprimary outcome was reduced with complete revascularization in the 2,479 patients with QCA stenosi

157 that were caused by both the need for repeat revascularization in the left anterior descending artery

158 n without a diagnostic angiogram or trial of revascularization in the preceding 90 days regardless of

159 d the need for first and subsequent coronary revascularizations in statin-treated patients with eleva

160 uring follow-up but a higher total number of revascularizations including the randomized treatment.

161 Over the past decade, use of revascularization increased among veterans with critical

162 use death, any myocardial infarction, or any revascularization; individual components of the composit

163 Coronary revascularization is accomplished either by percutaneous

164 ve rescue option when regular arterial graft revascularization is not feasible.

165 Revascularization is often performed in patients with st

166 migrate to the areas of damage and stimulate revascularization largely by paracrine activation of ang

167 ete versus 76% (95% CI, 74-80) with complete revascularization (log-rank test: P=0.02) after off-pump

168 ferral of younger patients for multiarterial revascularization may address this practice gap.

169 ssel disease, stress echocardiography-guided revascularization may not be significantly different to

170 was large site-level variation in the use of revascularization (median rate, 41.7% [interquartile ran

171 irectly associated with timely initiation of revascularization, missed, misdiagnosis or late diagnosi

172 ardiac events; readmission reasons varied by revascularization modality.

173 rterial disease level groups, they underwent revascularization more often.

174 which was a composite of SVG occlusion, SVG revascularization, myocardial infarction in myocardial t

175 ere observed in total (first and subsequent) revascularizations (negative binomial rate ratio, 0.64 [

176 revealed a hazard ratio incomplete/complete revascularization of 1.19 (95% CI, 1.01-1.39; P=0.04).

177 ate the severity of stenosis, and that after revascularization of a CTO, the index of ischemia may in

178 Eluting Absorbable Polymer Stent System for Revascularization of Coronary Arteries; n=1398) is a pro

179 r angioplasty is the preferred treatment for revascularization of femoropopliteal lesions in peripher

180 ediated chemotaxis of macrophages and slowed revascularization of injured muscle.

181 , migration to areas of vascular damage, and revascularization of ischemic areas in pathologic condit

182 etic stem progenitor cells (HSPCs) stimulate revascularization of ischemic areas.

183 Revascularization of ischemic tissues is a major barrier

184 Although clinical evidence indicates that revascularization of the ischemic brain regions is cruci

185 howed complete local tumor control, 1 showed revascularization of the scleral melt, and 1 required or

186 The benefit of complete revascularization on hard clinical outcomes emerged main

187 nfarct expansion after stroke, the effect of revascularization on poststroke neuroinflammation and th

188 freedom from clinically driven target-lesion revascularization or access-circuit thrombosis during th

189 ardiovascular events, while prior peripheral revascularization or amputation is associated with great

190 icantly associated with a lower incidence of revascularization or endovascular surgery and lower extr

191 The IRONIC trial (Invasive Revascularization or Not in Intermittent Claudication) r

192 e or probable stent thrombosis, or unplanned revascularization or rehospitalization for progressive a

193 is, PAD events (critical limb ischemia, limb revascularization, or amputation for ischemia) and VTE (

194 , any stroke, any myocardial infarction, any revascularization, or Bleeding Academic Research Consort

195 ardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angin

196 d as all-cause death, myocardial infarction, revascularization, or stroke.

197 ardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospital

198 Revascularization outcomes are largely unknown in SCAD p

199 ) in the FFR group met criteria to recommend revascularization (P = 0.11).

200 CAC-absent group was associated with reduced revascularization (P<0.0001).

201 tack, heart failure hospitalization, cardiac revascularization, peripheral arterial disease intervent

202 The input signals governing this pro-revascularization phenotype remain of interest.

203 ogram in macrophages characteristic of a pro-revascularization phenotype.

204 dial infarction with initial angiography and revascularization plus guideline-based medical therapy (

205 terventions were combination of endovascular revascularization plus supervised exercise (n = 106) or

206 Combining endovascular revascularization plus supervised exercise shows promisi

207 ovascular events either following a coronary revascularization procedure (percutaneous coronary inter

208 was associated with an increased hazard of a revascularization procedure during follow-up (HR 2.50; 9

209 s with a first open surgical or endovascular revascularization procedure in the lower extremities or

210 s are readmitted within 30 days of a carotid revascularization procedure.

211 The total number of revascularization procedures (including randomized treat

212 nation therapy resulted in a lower number of revascularization procedures during follow-up but a high

213 , progression to critical limb ischemia, and revascularization procedures during follow-up.

214 , atrial fibrillation, valvular disease, and revascularization procedures).

215 , fatal coronary events, silent infarctions, revascularization procedures, or resuscitated cardiac ar

216 h symptomatic PAD undergoing lower extremity revascularization randomized to rivaroxaban 2.5 mg twice

217 Overall, 90-day revascularization rate was 52%, and women were less like

218 16 were used to compare mortality and repeat revascularization rates for HCR and conventional CABG af

219 Prespecified analyses examined all coronary revascularizations, recurrent revascularizations, and re

220 nonculprit lesions with the aim of complete revascularization reduced major cardiovascular (CV) even

221 ultivessel coronary artery disease, complete revascularization reduced major CV outcomes to a greater

222 However, whether revascularization reduces death and other cardiovascular

223 rivaroxaban to aspirin after lower extremity revascularization regardless of concomitant clopidogrel,

224 intervention for revascularization, deferred revascularization remained associated with a higher risk

225 imary patency and freedom from target lesion revascularization remained superior compared with conven

226 cute coronary syndrome (ACS) treated without revascularization remains unknown.

227 before invasive treatment for IC, but early revascularization remains widespread, especially in pati

228 Here, we show that revascularization requires a coordinated multi-tissue re

229 r women, often treated conservatively due to revascularization risks.

230 ry disease who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice

231 he brain even following early and successful revascularization.SIGNIFICANCE STATEMENT This study addr

232 stolic blood pressure (SBP) after successful revascularization (SR) via endovascular therapy (EVT) is

233 Although revascularization strategies significantly reduce mortal

234 (ISCHEMIA) and Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Diseas

235 differences in general and according to the revascularization strategies.

236 failure according to the different coronary revascularization strategies.

237 re randomly assigned to one of the following revascularization strategies: either percutaneous corona

238 ermine the association between an FFR-guided revascularization strategy and all-cause mortality at 1

239 The optimal revascularization strategy for acute limb ischemia (ALI)

240 d trials are needed to determine the optimal revascularization strategy for ALI.

241 After 5 years of follow-up, a revascularization strategy had lost its early benefit an

242 was no interaction between sex and coronary revascularization strategy regarding mortality and renal

243 A revascularization strategy resulted in almost twice the

244 t of stable angina), and in the selection of revascularization strategy.

245 tratified them according to their individual revascularization strategy.

246 was a composite of nonfatal AMI, unscheduled revascularization, stroke, all-cause death, heart failur

247 e composite of myocardial infarction, repeat revascularization, stroke, or death (termed major cardio

248 CVD events (myocardial infarction, coronary revascularization, stroke, or death), and whether it was

249 rizations, recurrent revascularizations, and revascularization subtypes.

250 the BioFreedom stent group had target lesion revascularization than those in the Orsiro stent group (

251 these results uncover a role of ALX/FPR2 in revascularization that may be amenable to therapeutic ta

252 after 1 year and higher rates of subsequent revascularization that were caused by both the need for

253 When AC is required for rescue graft revascularization, the conduit placement site seems to b

254 ifferent to complete angiographically guided revascularization, thereby reducing the need for electiv

255 utcomes of primary patency and target lesion revascularization (TLR) estimated with Kaplan-Meier anal

256 he COMPLETEs trial (Complete vs Culprit-Only Revascularization to Treat Multi-Vessel Disease After Ea

257 In the COMPLETE (Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Ea

258 s myocardial infarction, coronary or carotid revascularization, transient ischemic attack, or stroke.

259 ed, randomized Hybrid Trial (Hybrid Coronary Revascularization Trial) was initiated to examine whethe

260 sis of 10-year outcomes of the ART (Arterial Revascularization Trial).

261 ypass Surgery for Effectiveness of Left Main Revascularization) trial.

262 nty arises from particular challenges facing revascularization trials.

263 ypass Surgery for Effectiveness of Left Main Revascularization) trials; the Fourth Universal Definiti

264 d of undergoing endovascular versus surgical revascularization using a logistic regression model.

265 ches for randomized trials comparing routine revascularization versus an initial conservative strateg

266 % and that of major amputation or peripheral revascularization was 41.9%.

267 te-level, and procedural factors, FFR-guided revascularization was associated with a 43% lower risk o

268 In adjusted analyses, revascularization was associated with a lower risk of mo

269 Revascularization was associated with a reduced nonproce

270 In patients with ALI, endovascular revascularization was associated with better in-hospital

271 come of CV death, new MI, or ischemia-driven revascularization was determined.

272 Freedom from revascularization was estimated with Kaplan-Meier analys

273 Acute revascularization was lower in STEMI-SCAD (70% vs. 97%);

274 Ischemia-driven revascularization was more frequent after PCI than after

275 Repeat revascularization was more frequent with FFR-guided PCI

276 Clinically driven target lesion revascularization was necessary in 14% of DCB patients v

277 Revascularization was not a cost-effective treatment opt

278 with stable ischemic heart disease, routine revascularization was not associated with improved survi

279 ographic findings were all well-balanced and revascularization was performed equally effective, the a

280 914) hospitalizations for ALI, endovascular revascularization was performed in 5008 (47.8%) and surg

281 between sexes, whereas prior lower extremity revascularization was reported less frequently in women

282 d 365-day clinically indicated target lesion revascularization was significantly lower with DCS (7.2%

283 on between CAC and 90-day high-grade CAD and revascularization were assessed.

284 Four-year MI rates in patients undergoing revascularization were more frequent with the invasive v

285 on myocardial infarction who did not undergo revascularization were randomized to prasugrel or clopid

286 peripheral artery disease who had undergone revascularization were randomly assigned to receive riva

287 First revascularizations were reduced to 9.2% (22.5/1000 patie

288 infarction, or ischemia-driven target lesion revascularization) were assessed and compared after perc

289 freedom from clinically driven target lesion revascularization when compared with PTA (Kaplan-Meier e

290 n initial invasive strategy (angiography and revascularization when feasible) and medical therapy or

291 The acute setting of peripheral revascularization which involves plaque rupture and endo

292 (myocardial infarction, ischemic stroke, and revascularization with coronary artery bypass graft surg

293 After peripheral revascularization with or without post-procedure MALE ho

294 ructive coronary artery disease benefit from revascularization with percutaneous coronary interventio

295 at substantial risk for long-term MACE after revascularization with percutaneous coronary interventio

296 Complete revascularization with routine percutaneous coronary int

297 her than the target lesion, or target lesion revascularization within 1 year, analyzed by intention-t

298 s unlikely to have high-grade CAD or require revascularization within 90 days and unlikely to experie

299 tifies patients unlikely to undergo coronary revascularization within 90 days of a PET/CT.

300 iod, there was a temporal increase in use of revascularization within 90 days of hospitalization-endo